A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints

@article{Dalhoff2009ALJ,
  title={A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints},
  author={A. Dalhoff and P. Ambrose and J. Mouton},
  journal={Infection},
  year={2009},
  volume={37},
  pages={296-305}
}
AbstractSince the origin of an "‘International Collaborative Study on Antibiotic Sensitivity Testing’" in 1971, considerable advancement has been made to standardize clinical susceptibility testing procedures of antimicrobial agents. However, a consensus on the methods to be used and interpretive criteria was not reached, so the results of susceptibility testing were discrepant. Recently, the European Committee on Antimicrobial Susceptibility Testing achieved a harmonization of existing methods… Expand
MASTER: a model to improve and standardize clinical breakpoints for antimicrobial susceptibility testing using forecast probabilities
TLDR
It is demonstrated that CBPs can be improved and standardized by minimizing methodological categorization error rates and ZMUs may be introduced if an intermediate zone is not appropriate for pharmacokinetic/pharmacodynamic or drug dosing reasons. Expand
Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
The imipenem and meropenem breakpoints for Enterobacteriaceae established by the Clinical and Laboratory Standards Institute (CLSI) are somewhat lower than those established by the European CommitteeExpand
The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds.
TLDR
The epidemiological cut off value is focused on, the new interpretive endpoint that will identify the non-wild type strains (defined as potentially harboring resistance mechanisms), because the former do not account for the pharmacology of the antifungal agent or the findings from clinical outcome studies. Expand
New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
  • T. Gumbo
  • Medicine
  • Antimicrobial Agents and Chemotherapy
  • 2010
TLDR
Current critical concentrations of first-line antituberculosis drugs are overoptimistic and should be set lower with the proposed breakpoints, because the rates of multidrug-resistant tuberculosis could become 4-fold higher than currently assumed. Expand
Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
  • M. Labreche, C. Frei
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2012
TLDR
Evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic-pharmacodynamic targets in order to maintain acceptable clinical outcomes. Expand
Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.
TLDR
Population kinetics and MCS are required to determine robust species-specific interpretive criteria (susceptible, intermediate, and resistant classifications) for antimicrobial susceptibility testing breakpoints (taking into account interanimal variability). Expand
Advanced Phenotypic Antimicrobial Susceptibility Testing Methods
TLDR
This chapter will address rapid phenotypic susceptibility testing methods, which mean that detection of growth from a pure culture with a defined inoculum is determined more rapidly than can be done with traditional methods. Expand
Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia
TLDR
It is revealed that patients with Acinetobacter bacteremia treated with a carbapenem had a more favorable outcome when the carbapENem MICs of their isolates were ≤4 mg/liter than those withMICs of ≥8mg/liter. Expand
En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach
TLDR
The procedures and reviews scientific options to solve challenges for the determination of specific CBPs for animal species, drug substances and disease conditions are outlined and expert comments and/or recommendations associated with CBPs are vetted to facilitate their sound implementation in a clinical setting. Expand
Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.
TLDR
Etest is suitable to test micafungin for most of the Candida species evaluated and the number of resistant isolates was small, so further evaluations are needed with a higher number of such isolates including more resistant or those with known mechanisms of resistance (non-WT). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
TLDR
This paper attempts to summarize the philosophy of the British Society for Antimicrobial Chemotherapy (BSAC) Working Party in its approach to setting breakpoints and to update the activities of the Working Party since it initially published breakpoints, approximately 10 years ago. Expand
Impact of pharmacodynamics on breakpoint selection for susceptibility testing.
  • J. Mouton
  • Medicine
  • Infectious disease clinics of North America
  • 2003
In their report, Ericsson and Sherris stated that "adequately described sensitivity categorization schemes have been based on four main concepts" and went on to describe the advantages and inherentExpand
Antimicrobial Susceptibility Breakpoints
  • P. Ambrose
  • Medicine
  • Treatments in respiratory medicine
  • 2005
TLDR
The youthful science of pharmacokinetics-pharmacodynamics provides a useful platform to determine which pneumococcal strains with elevated MIC values can be treated with contemporary dosing regimens and also facilitates the proper selection of antimicrobial breakpoints for all antimicrobial classes, including the newer macrolides. Expand
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
TLDR
Stochastic methods utilizing patient population pharmacokinetics, target organism minimum inhibitory concentration distributions, and PK-PD targets from non-clinical models of infection or clinical data have established a new paradigm for determining in vitro susceptibility breakpoints and selection of empirical therapy in clinical practice. Expand
Development of in vitro susceptibility testing criteria and quality control parameters
TLDR
The NCCLS Subcommittee attempts to generate semiannual supplemts of its reference tables to reflect the addition of new antimicrobial agents and to correct data for older drugs. Expand
Monte Carlo Simulation in the Evaluation of Susceptibility Breakpoints: Predicting the Future: Insights from the Society of Infectious Diseases Pharmacists
TLDR
Pharmacokinetic‐pharmacodynamic target attainment analyses using Monte Carlo simulation to integrate interpatient variability in drug exposure, drug potency, and in vivo exposure targets predictive of positive therapeutic outcomes are influencing antibacterial susceptibility breakpoints at home and abroad. Expand
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
  • D. Andes, W. Craig
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2005
Susceptibility surveillance investigations have demonstrated an increased incidence of ESBL-producing Gram-negative bacilli. Case cohort studies have suggested clinical relevance associated withExpand
History and development of antimicrobial susceptibility testing methodology.
  • P. Wheat
  • Medicine, Biology
  • The Journal of antimicrobial chemotherapy
  • 2001
TLDR
The history and development of some methods still in common use for routine AST, e.g. disc diffusion and agar dilution are traced, to increase the speed and reliability of resistance testing, the use of a genotypic approach has been advocated. Expand
Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.
TLDR
Children 12 years of age were significantly more likely to be infected with a penicillin-resistant pneumococcus than were adolescents or adults, and this finding may explain the lack of clinical response in patients treated with these antibiotics. Expand
The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome
TLDR
Pharmacokinetic/pharmacodynamic surrogate relationships have been used to describe the antibacterial activity of various classes of antimicrobial agents and AUIC24 may prove to be an important pharmacokinetic surrogate if both time and concentration are indeed important parameters. Expand
...
1
2
3
4
5
...